SEQUENCE LISTING

<110> Laus, Reiner
Hakim, Itzhak
Vidovic, Damir

<120> Compositions and Methods for Enhancement of Major Histocompatibility Complex Class I Restricted Antigen Presentation

<130> 57636-8020.US00

<140> US 09/461,684
<141> 1999-12-14

<150> US 60/112,324
<151> 1998-12-14

<160> 10

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> pK

C1

<400> 1
Cys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15
Lys Lys Lys Lys Lys
20

<210> 2
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> pEA

<400> 2
Cys Glu Ala Ala Ala Ala Ala Glu Ala Ala Ala Ala Ala Glu Ala Ala
1 5 10 15
Ala Ala Ala Glu Ala Ala Ala Ala Ala
20 25

<210> 3
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> HA

<400> 3
Cys Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Trp Glu
1 5 10 15
Gly Met Ile Asp Gly Trp Tyr Gly
20

<210> 4
<211> 45
<212> PRT
<213> Artificial Sequence

<220>
<223> tandem pEA/pK conjugate

<400> 4
Cys Glu Ala Ala Ala Ala Ala Glu Ala Ala Ala Ala Ala Glu Ala Ala
1 5 10 15
Ala Ala Ala Glu Ala Ala Ala Ala Ala Lys Lys Lys Lys Lys Lys Lys
20 25 30
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
35 40 45

<210> 5
<211> 44
<212> PRT
<213> Artificial Sequence

<220>
<223> tandem HA/pK conjugate

C1

<400> 5
Cys Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Trp Glu
1 5 10 15
Gly Met Ile Asp Gly Trp Tyr Gly Lys Lys Lys Lys Lys Lys Lys Lys
20 25 30
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
35 40

<210> 6
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> added peptidic sequence with a combination of lys and arg residues, with an N-terminal cys residue

<221> VARIANT
<222> (1)...(21)
<223> Xaa = Arg or Lys

<400> 6
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Xaa
20

<210> 7
<211> 20
<212> PRT

<213> Artificial Sequence

<220>
<223> added peptidic sequence with a combination of lys and arg residues

<221> VARIANT
<222> (1)...(20)
<223> Xaa = Arg or Lys

<400> 7
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1   5   10   15
Xaa Xaa Xaa Xaa
            20

<210> 8
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> peptidic sequence with repeating subunits, with an N-terminal cys residue

<221> VARIANT
<222> (2)...(2)
<223> Xaa = Glu or Asp

<221> VARIANT
<222> (3)...(7)
<223> Xaa = Ala, Leu, Ile, Phe, Gly, Cys, Met or Val

<221> VARIANT
<222> (2)...(7)
<223> amino acids 2 to 7 comprise a subunit that is repeated three or more times

<400> 8
Cys Xaa Xaa Xaa Xaa Xaa Xaa
 1   5

<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> peptidic sequence with repeating subunits

<221> VARIANT
<222> (1)...(1)
<223> Xaa = Glu or Asp

<221> VARIANT
<222> (2)...(6)
<223> Xaa = Ala, Leu, Ile, Phe, Gly, Cys, Met or Val

<221> VARIANT
<222> (1)...(6)

<223> amino acids 1 to 6 comprise a subunit that is repeated three or more times

<400> 9
Xaa Xaa Xaa Xaa Xaa Xaa
1 5

<210> 10
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> OVA- derived peptide (OVA 257-264), recognized by the T cell hybridoma B3Z. (Jameson et al., 1993, J. Exp. Med. 177: 1541)

<400> 10
Ser Ile Ile Asn Phe Glu Lys Leu
1 5